Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec:156:103118.
doi: 10.1016/j.critrevonc.2020.103118. Epub 2020 Oct 3.

BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients

Umberto Malapelle  1 , Giulio Rossi  2 , Pasquale Pisapia  1 , Massimo Barberis  3 , Fiamma Buttitta  4 , Francesca Castiglione  5 , Fabiana Letizia Cecere  6 , Antonio Maria Grimaldi  7 , Antonino Iaccarino  1 , Antonio Marchetti  4 , Daniela Massi  5 , Daniela Medicina  8 , Fabio Mele  9 , Roberta Minari  10 , Elisabetta Orlando  11 , Fabio Pagni  12 , Giuseppe Palmieri  13 , Luisella Righi  14 , Alessandro Russo  15 , Stefania Tommasi  9 , William Vermi  8 , Giancarlo Troncone  16
Affiliations
Review

BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients

Umberto Malapelle et al. Crit Rev Oncol Hematol. 2020 Dec.

Abstract

In the era of personalized medicine, BRAF mutational assessment is mandatory in advanced-stage melanoma and non-small cell lung cancer (NSCLC) patients. The identification of actionable mutations is crucial for the adequate management of these patients. To date various drugs have been implemented in clinical practice. Similarly, various methods may be adopted for the identification of BRAF mutations. Here, we briefly review the current literature on BRAF in melanoma and NSCLC, focusing attention in particular on the different methods and drugs adopted in these patients. In addition, an overview of the real-world practice in different Italian laboratories with high expertise in molecular predictive pathology testing is provided.

Keywords: BRAF; Lung cancer; Melanoma; Precision medicine; Predictive molecular pathology.

PubMed Disclaimer